Satellos expects to begin first-in-human clinical trials mid-year for SAT-3247, an oral small molecule drug candidate in development as a novel regenerative medicine approach to treating DMD
.
Satellos Bioscience Inc. announced the formation of a Clinical Advisory Board comprised of distinguished clinical research leaders and experts in drug development in genetic muscle disorders,.
This randomized clinical trial compares the efficacy and adverse effects of the 3 most frequently prescribed corticosteroid regimens for boys with Duchenne musc
Risdiplam Promising for Spinal Muscular Atrophy medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.